Sexual & reproductive GnRH antagonist
Degarelix
Regulatory status
Status at a glance
503A compounding status
Not nominated
We found no pending nomination for the 503A bulks list. Unless the substance has another legal pathway (for example, a USP monograph or use in an FDA-approved drug), 503A pharmacies generally may not compound with it.
- FDA approval
- An FDA-approved product contains this peptide
- 503B outsourcing
- Not determined
- Anti-doping (WADA)
- Not on the WADA Prohibited List
- DEA schedule
- Not a controlled substance
About peptide status
Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.
This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.
If you think you are having a medical emergency, call 911.
Key takeaway
Degarelix (sold as Firmagon) is a synthetic decapeptide that blocks the gonadotropin-releasing hormone receptor, dropping testosterone to castrate levels within a few days and without the initial surge seen with older hormone drugs. It is used to treat advanced prostate cancer and lowers testosterone to castrate levels faster than the agonist leuprolide. It has been FDA-approved in the U.S. since 2008 and is given as a monthly subcutaneous injection.
At a glance
- What it is
- A GnRH receptor antagonist peptide that suppresses testosterone without a flare
- Approved for
- Advanced prostate cancer
- Key fact
- In a phase 3 trial it matched leuprolide for maintaining castrate testosterone over a year and lowered testosterone faster
- Route
- Subcutaneous injection (a loading dose, then monthly)
- Evidence strength
- FDA approved
Summary
Degarelix is an FDA-approved GnRH antagonist for advanced prostate cancer that lowers testosterone quickly. Learn how it works and its side effects.
What is degarelix?
Degarelix, sold under the brand Firmagon, is a synthetic ten-amino-acid peptide that acts as an antagonist at the gonadotropin-releasing hormone (GnRH) receptor. Where agonists such as leuprolide and goserelin first stimulate the pituitary before suppressing it, degarelix blocks the receptor directly from the first dose. It was developed by Ferring under the code FE200486 and approved in the United States in 2008.
How does degarelix work?
Degarelix binds reversibly and competitively to GnRH receptors on the pituitary, immediately blocking the hormone signal that normally drives release of luteinizing hormone and follicle-stimulating hormone. Those gonadotropins fall within hours, and testosterone drops to castrate levels within a few days. Because it is an antagonist rather than an agonist, it causes no initial testosterone surge, so there is no need for the anti-androgen cover used to blunt the "flare" with agonist drugs.
In advanced prostate cancer, removing testosterone deprives hormone-sensitive tumor cells of the signal they depend on. In the phase 3 CS21 trial, degarelix was non-inferior to leuprolide for keeping testosterone at or below castrate levels over 12 months, and it suppressed testosterone and PSA more quickly in the first weeks. That rapid onset without a flare is the main clinical distinction of the drug.
Is it FDA-approved?
Editor’s note
Status: Yes. Degarelix was approved by the FDA in 2008 for advanced prostate cancer. It is given as a subcutaneous injection, starting with a loading dose followed by a maintenance dose every 28 days.
Category: FDA-approved · Primary body area: Sexual & reproductive
Yes. Degarelix was approved by the FDA in 2008 for advanced prostate cancer. It is given as a subcutaneous injection, starting with a loading dose followed by a maintenance dose every 28 days.
What is degarelix prescribed for?
Degarelix is prescribed for the treatment of advanced (hormone-sensitive) prostate cancer. Its rapid, flare-free testosterone suppression makes it useful when a fast drop in testosterone is desirable, such as in men with symptomatic or high-burden disease.
What are the side effects?
According to the prescribing information, common side effects include:
- Injection-site reactions such as pain, redness, and swelling (common with the loading dose)
- Hot flashes
- Weight gain and fatigue
- Increased liver enzymes
More serious considerations include:
- QT-interval prolongation, so caution is advised with other QT-prolonging drugs or electrolyte abnormalities
- Hypersensitivity reactions
- Reduced bone density with long-term androgen deprivation
Sources: FDA prescribing information for Firmagon; the CS21 phase 3 trial (Klotz et al., BJU International, 2008, DOI: 10.1111/j.1464-410X.2008.08183.x), indexed on PubMed. This document is educational and does not constitute medical advice.
Registered human trials
0 registered human trials on ClinicalTrials.gov that we reviewed
Sources
- [1]
- [2]
Compare every peptide’s status in the peptide regulatory status database
More for Sexual & reproductive
View all sexual & reproductive peptides →- FDA-approved Sexual & reproductive
Cetrorelix
Cetrorelix is a synthetic ten-amino acid peptide that blocks the GnRH receptor in the pituitary gland, shutting down the hormone signals that would otherwise trigger early ovulation. It is FDA-approved as Cetrotide, a subcutaneous injection used during IVF to stop a premature LH surge so that eggs can mature and be collected on schedule. It remains a standard part of modern IVF stimulation, valued for acting quickly and for lowering the risk of ovarian hyperstimulation compared with older protocols.
- Not FDA-approved Sexual & reproductive
Compounded-Gonadorelin
It Is and What
Gonadorelin is a synthetic form of the natural reproductive hormone GnRH, used in wellness and men's-health settings as an add-on to testosterone therapy to help preserve fertility and testicular size. The strongest human data come from a different setting. In a 2021 meta-analysis of 420 men with congenital hypogonadotropic hypogonadism across seven studies, pulsatile GnRH began sperm production 5.3 months earlier than gonadotropin therapy (p = 0.004), with no significant difference in sperm concentration (p = 0.37) or pregnancy rate (p = 0.11). Direct evidence for the testosterone add-on use is limited, and there is no FDA-approved gonadorelin product for it.
- FDA-approved Sexual & reproductive
Ganirelix
Ganirelix (originally approved as Antagon) is a synthetic decapeptide that blocks the gonadotropin-releasing hormone receptor, used during fertility treatment to stop an egg from being released too early. Given once daily during ovarian stimulation, it prevents the premature luteinizing hormone surge that could otherwise disrupt an IVF cycle. It has been FDA-approved in the U.S. since 1999 and is given as a small daily subcutaneous injection.
- FDA-approved Sexual & reproductive
Goserelin
Goserelin (goserelin acetate, sold as Zoladex) is a synthetic decapeptide agonist of gonadotropin-releasing hormone delivered as a small implant that suppresses the body's production of testosterone and estrogen. It is used across prostate cancer, breast cancer, and endometriosis, and in one long-term breast-cancer trial it matched standard chemotherapy for survival in certain premenopausal women. It has been FDA-approved in the U.S. since 1989 and is given as a monthly or three-month depot implant.
- FDA-approved Sexual & reproductive
Histrelin
Histrelin (histrelin acetate, sold as Supprelin LA and formerly as Vantas) is a synthetic nonapeptide agonist of gonadotropin-releasing hormone delivered as a small implant that releases drug for about a year. It suppresses the pituitary and the sex hormones it controls, and is used for central precocious puberty in children; a second implant for advanced prostate cancer in adults was discontinued in 2021. The implant products have been FDA-approved in the U.S. since the mid-2000s, and one implant lasts roughly 12 months.
- FDA-approved Sexual & reproductive
Human-Chorionic-Gonadotropin
Human chorionic gonadotropin (hCG; FDA-approved injectable brands include Pregnyl and Novarel) is a placental hormone that acts like luteinizing hormone, triggering ovulation in women and testosterone production in men. It is used in fertility treatment, in male hypogonadotropic hypogonadism, and for undescended testicles in boys, and it is not approved for weight loss. In a Cochrane review of seven trials with 1,136 women, recombinant and urinary hCG gave similar ongoing pregnancy or live-birth rates (odds ratio 1.15, 95% confidence interval 0.89 to 1.49).